Effects of increased liver blood flow on the kinetics and dynamics of recombinant tissue-type plasminogen activator

Clinical Pharmacology and Therapeutics

Volumn 60, Issue 5, 1996, Pages 504-511

  Van Griensven, Jean M T ^a,b,c   Huisman, Linda G M ^a,b   Stuurman, Thea ^a,b   Dooijewaard, Gerard ^a,b   Kroon, Ria ^a,b   Schoemaker, Rik C ^a,b   Kluft, Kees ^a,b   Cohen, Adam F ^a,b  

^a Gaubius Laboratory ^*

^b TNO   (Netherlands)

^c CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; INDOCYANINE GREEN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; HUMAN; HUMAN EXPERIMENT; LIVER BLOOD FLOW; MALE; NORMAL HUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOLUNTEER;

EID: 0029801342     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(96)90146-0     Document Type: Article

References (41)

1. Mathey DG, Schofer J, Sheehan FH, Becher H, Tilsner V, Dodge HT. Intravenous urokinase in acute myocardial infarction. Am J Cardiol 1985;55:878-82.
2. Van der Werf F, Vanhaecke J, de Geest H, Verstraete M, Collen D. Coronary thrombolysis with recombinant single-chain urokinase-type plasminogen activator in patients with acute myocardial infarction. Circulation 1986;74:1066-70.
3. Verstraete M. Thrombolytic treatment in acute myocardial infarction. Circulation 1990;82:II96-109.
4. Meyer J, Bär F, Barth H, Charbonnier B, El Deeb MF, Erbel R, et al. Randomised double-blind trial of recombinant pro-urokinase against streptokinase in acute myocardial infarction. Lancet 1989;1:863-8.
5. Goldhaber SZ, Buring JE, Lipnick RJ, Hennekens CH. Pooled analyses of randomized trials of streptokinase and heparin in phlebographically documented acute deep venous thrombosis. Am J Med 1984;76: 393-7.
6. Lechler E, Meyer-Börnecke D, Winter UJ, Schultz V. Intermittent high dosage scheme of streptokinase/ urokinase in fibrinolytic therapy [abstract]. Thromb Haemost 1985;54:272.
7. Goldhaber SZ, Vaughen DE, Markis JE, Selwyn AP, Meyerovitz MF, Loscalzo J, et al. Acute pulmonary embolism treated with tissue plasminogen activator. Lancet 1986;2:886-9.
8. Leeper KV Jr, Popovich J Jr, Lesser BA, Adams D, Froelich JW, Burke MW, et al. Treatment of massive acute pulmonary embolism: the use of low doses of intrapulmonary arterial streptokinase combined with full doses of systemic heparin. Chest 1988;93:234-40.
9. Garabedian HD, Gold HK, Leinbach RC, Yasuda T, Johns JA, Collen D. Dose-dependent thrombolysis, pharmacokinetics and hemostatic effects of recombinant human tissue-type plasminogen activator for coronary thrombosis. Am J Cardiol 1986;58:673-9.
10. Emeis JJ, van den Hoogen CM, Jense D. Hepatic clearance of tissue-type plasminogen activator in rats. Thromb Haemost 1985;54:661-4.
11. Einarsson M, Smedsrod B, Pertoft H. Uptake and degradation of tissue plasminogen activator in rat liver. Thromb Haemost 1988;59:474-9.
12. Topol EJ, Bell WR, Weisfeldt ML. Coronary thrombolysis with recombinant tissue-type plasminogen activator. Ann Intern Med 1985;103:837-43.
13. Verstraete M, Bory M, Collen D, Erbel R, Lennane RJ, Mathey D, et al. Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Lancet 1985;1:842-7.
14. Verstraete M, Bleifeld W, Brower RW, Charbonnier W, Collen D, De Bono DP, et al. Double-blind randomised trial of intravenous tissue-type plasminogen activator versus placebo in acute myocardial infarction. Lancet 1985;2:965-9.
15. Koster RW, Cohen AF, Kluft C, Kasper FJ, Van der Wouw PA, Weatherley BC. The pharmacokinetics of recombinant double-chain t-PA (duteplase): Effects of bolus injection, infusion, and administration by weight in patients with myocardial infarction. Clin Pharmacol Ther 1991;50:267-77.
16. Stump DC, Califf RM, Topol EJ, Sigmon K, Thornton D, Masek R, et al. Pharmacodynamics of thrombolysis with recombinant tissue-type plasminogen activator. Correlation with characteristics of and clinical outcomes in patients with acute myocardial infarction. Circulation 1989;80:1222-30.
17. De Boer A, Kluft C, Kroon JM, Kasper FJ, Schoemaker HC, Pruis J, et al. Liver blood flow as a major determinant of the clearance of recombinant human tissue-type plasminogen activator. Thromb Haemost 1992;67:83-7.
18. van Griensven JM, Burggraaf J, Huisman LG, Koster RW, Kroon R, Cohen AF. Liver blood flow affects the plasma concentrations of tissue-type plasminogen activator in patients with acute myocardial infarction [abstract]. Circulation 1994;90:I553.
19. Svensson CK, Edwards DJ, Mauriello PM, Barde SH, Foster AC, Lane RA, et al. Effect of food on hepatic blood flow: implications in the "food effect" phenomenon. Clin Pharmacol Ther 1983;34:316-23.
20. Svensson CK, Cumella JC, Tronolone M, Middleton E Jr, Lalka D. Effect of hydralazine, nitroglycerin, and food on estimated hepatic blood flow. Clin Pharmacol Ther 1985;37:464-8.
21. Moneta GL, Taylor DC, Helton WS, Mulholland MW, Strandness DE Jr. Duplex ultrasound measurement of postprandial intestinal blood flow: Effect of meal composition. Gastroenterology 1988;95:1294-301.
22. Brandt JL, Castleman L, Ruskin HD, Greenwald J, Kelly JJ. The effect of oral protein and glucose feeding on splanchnic blood flow and oxygen utilization in normal and cirrhotic subjects. J Clin Invest 1955;34: 1017-25.
23. Orrego H, Mena I, Baraona E, Palma R. Modifications in hepatic blood flow and portal pressure produced by different diets. Am J Dig Dis 1965;10:239-48.
24. Koster T, Caekebeke-Peerlinck KMJ, Briet E. A randomized and blinded comparison of the sensitivity and the reproducibility of the Ivy and Simplate II bleeding time techniques. Am J Clin Pathol 1989;92: 315-20.
25. Caesar J, Shaldon S, Chiandussi L, Guevara L, Sherlock L. The use of indocyanine green in the measurement of hepatic blood flow and as a test of hepatic function. Clin Sci 1961;21:43-57.
26. Leevy CM, Mendenhall CL, Lesko W, Howard MM. Estimation of hepatic blood flow with indocyanine green. J Clin Invest 1962;41:1169-79.
27. Leevy CM, Smith F, Longueville J, Paumgartner G, Howard MM. Indocyanine green clearance as a test for hepatic function. Evaluation by dichromatic ear densitometry. JAMA 1967;200:148-52.
28. Villeneuve JP, Huot R, Marleau D, Huet PM. The estimation of hepatic blood flow with indocyanine green: comparison between the continuous infusion and single injection methods. Am J Gastroenterol 1982;77:233-7.
29. Meijer DKF, Weert B, Vermeer GA. Pharmacokinetics of biliary excretion in man; VI: indocyanine green. Eur J Clin Pharmacol 1991;35:295-303.
30. Burns E, Ball CE, Christie JP, Broadhead GD, Tucker GT, Bax NDS. Direct and indirect measurement of the hepatic extraction ratio of indocyanine green in the rat. Br J Clin Pharmacol 1989;76:503-8.
31. Rappaport PL, Thiessen JJ. High-pressure liquid chromatographic analysis of indocyanine green. J Pharm Sci 1982;71:157-61.
32. Rånby M, Bergsdorf N, Nilsson T, Mellbring G, Winblad B, Bucht G. Age dependence of tissue plasminogen activator concentrations in plasma, as studied by an improved enzyme-linked immunosorbent assay. Clin Chem 1986;32:2160-5.
33. Verheijen JH, Mullaart E, Chang GTG, Kluft C, Wijngaards G. A simple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma. Thromb Haemost 1982;48:266-9.
34. Binnema DJ, van Iersel JJL, Dooijewaard G. Quantitation of urokinase antigen in plasma and culture media by use of an ELISA. Thromb Res 1986;43:569-77.
35. van Hinsbergh VWM, van den Berg EA, Fiers W, Dooijewaard G. Tumor necrosis factor induces the production of urokinase-type plasminogen activator by human endothelial cells [abstract]. Blood 1990;75: 1991-8.
36. 2-antiplasmin activity with chromogenic substrates. Haemostasis 1985; 15:198-203.
37. Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957;17:237-46.
38. Koopman J, Haverkate F, Koppert P, Nieuwenhuizen W, Brommer EJP. New enzyme immunoassay of fibrin-fibrinogen degradation products in plasma using a monoclonal antibody. J Lab Clin Med 1987;109: 75-84.
39. Cohen AF, Burggraaf K, De Boer A. Clearance of plasminogen activators. A major determinant of plasma concentration: therapeutic and diagnostic implications, In: Brakman P, Kluft C, editors. Plasminogen activation in fibrinolysis, in tissue remodeling, and in development. Ann NY Acad Sci 1992:443-9.
40. Verstraete M, Su CAPF, Tanswell P, Feuerer W, Collen D. Pharmacokinetics and effects on fibrinolytic and coagulation parameters of two doses of recombinant tissue-type plasminogen activator in healthy volunteers. Thromb Haemost 1986;56:1-5.
41. van Griensven JMT, Burggraaf J, Gerloff J, Gunzler WA, Beier H, Kroon R, et al. Effects of changing liver blood flow by exercise and food on kinetics and dynamics of saruplase. Clin Pharmacol Ther 1995;57: 381-9.